Table 3.
Characteristics of Patients With Spasm‐Induced NSTE‐ACS According to Variant Angina
| Variant Angina (n=119) | Nonvariant Angina (n=201) | P Value | |
|---|---|---|---|
| Age, y | 59±11 | 62±11 | 0.01 |
| Males, % | 82% | 64% | 0.001 |
| Current smoking, % | 50% | 37% | 0.02 |
| Body mass index, kg/m2 | 23.6±3.7 | 23.6±3.4 | 0.95 |
| Family history of CAD, % | 24% | 20% | 0.44 |
| Previous medical history, % | |||
| Hypertension | 49% | 48% | 0.93 |
| Dyslipidemia | 44% | 59% | 0.007 |
| Diabetes mellitus | 17% | 18% | 0.71 |
| Previous MI | 3% | 4% | 0.55 |
| Elevated cardiac biomarkers | 36% | 26% | 0.06 |
| LVEF, % | 66.3±7.0 | 64.5±7.2 | 0.11 |
| Medications at discharge, % | |||
| Aspirin | 61% | 58% | 0.62 |
| Calcium channel blockers | 98% | 96% | 0.22 |
| β‐Blockers | 0% | 3% | 0.09 |
| ACEI | 6% | 9% | 0.30 |
| ARB | 8% | 16% | 0.04 |
| Nitrates | 61% | 41% | <0.001 |
| Nicorandil | 35% | 27% | 0.17 |
| Statins | 36% | 38% | 0.74 |
Data are mean±SD or n (%).NSTE‐ACS indicates non–ST‐segment elevation acute coronary syndrome; CAD, coronary heart disease; MI, myocardial infarction; LVEF, left ventricular ejection fraction; ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor antagonist.